Published in
Lippincott, Williams & Wilkins, Critical Care Medicine, 1(43), p. 57-64, 2015
DOI: 10.1097/ccm.0000000000000554
Links
Tools
Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX)*
Journal article published in 2015 by
Jean-Louis Vincent,
Christopher T. Privalle,
Mervyn Singer 
,
José A. Lorente,
José Ángel Lorente Balanza,
Erwin Boehm,
Andreas Meier-Hellmann,
Harald Darius,
Ricard Ferrer,
Josep-Maria Sirvent,
Gernot Marx,
Joseph DeAngelo
,
José A. Lorente,
José Ángel Lorente Balanza,
Erwin Boehm,
Andreas Meier-Hellmann,
Harald Darius,
Ricard Ferrer,
Josep-Maria Sirvent,
Gernot Marx,
Joseph DeAngelo
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The objective of this study is to compare the effectiveness and safety of the hemoglobin-based nitric oxide scavenger, pyridoxalated hemoglobin polyoxyethylene, against placebo in patients with vasopressor-dependent distributive shock.